Oral selective estrogen receptor degraders and biomarker-driven therapy in ER-positive breast cancer: mechanisms, clinical evidence, and future directions.

giredestrant (RG6171) - Roche

Orserdu (elacestrant) - Menarini

Inluriyo (imlunestrant) - Eli Lilly

Veppanu (vepdegestrant) - Rigel Pharmaceuticals

Etcamah (camizestrant) - AstraZeneca

fulvestrant - Generic mfg.

http://www.ncbi.nlm.nih.gov/pubmed/42657161

Anton Yu Alasheev; Elena V Petersen; Philipp Y Maximov; Raneem Hamama

Aug 28, 2026